insights_auto
Outlook: 51.7% bullish·10.3% bearish
Go to analysischevron_right
AZN:LON
AstraZeneca PLC (US)
GBX 13,982.00
arrow_upward
+0.37%(+52.00) 1D
Nov 13, 4:37:31 PM UTC · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AZN...
Open
GBX 13,902.00
High
GBX 14,064.00
Low
GBX 13,892.00
Mkt. cap
285.90B
Avg. vol.
2.49M
Volume
1.06M
Dividend
1.71%
Quarterly dividend
GBX 59.75
Ex-dividend date
Aug 6, 2026
P/E ratio
26.17
52-wk high
GBX 15,732.00
52-wk low
GBX 9,892.00
EPS
GBX 5.34
Shares outstanding
1.55B
No. of employees
96K
Open
GBX 13,902.00
High
GBX 14,064.00
Low
GBX 13,892.00
Mkt. cap
285.90B
Avg. vol.
2.49M
Volume
1.06M
Dividend
1.71%
Quarterly dividend
GBX 59.75
Ex-dividend date
Aug 6, 2026
P/E ratio
26.17
52-wk high
GBX 15,732.00
52-wk low
GBX 9,892.00
EPS
GBX 5.34
Shares outstanding
1.55B
No. of employees
96K
News stories
From web sources and news partners
Quantisnow
·
1 day ago
AZN Financials: Revenue $58.74B, Net Income $10.22B
www.tokenpost.com
·
1 day ago
AstraZeneca Cuts About 600 Marketing Jobs in Two Drug Businesses
Bloomberg.com
·
1 day ago
AstraZeneca Cuts 600 US Sales Staff as Savings Drive Kicks In
Yahoo Finance
·
4 days ago
Omniose Announces Its Acquisition by AstraZeneca
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About AstraZeneca PLC (US)
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorHealth Care
IndustryPharmaceutical industry
Websiteastrazeneca.com